(ECTRIMS) MS therapy GNbAC1 promotes myelin rejuvenation, study shows on: November 13, 2017, 05:33:39 pm #1 From Multiple Sclerosis News Today, October 30, 2017: MS Therapy GNbAC1 Promotes Myelin Rejuvenation, Trial Shows Read about a Phase 2b multiple sclerosis trial showing that GNbAC1 promotes the restoration of the myelin coating projecting nerve cells. Multiple Sclerosis News Today · multiplesclerosisnewstoday.com Logged MS Speaks--online for 20 yearsSPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) 12/16/20 - 3/16/24.
Update on temelimab (GNbAC1) Reply #1 on: April 27, 2020, 08:52:50 pm #2 Trials of GNbAC1 (temelimab) have been delayed due to the COVID-19 outbreak. Some information about it: Temelimab Temelimab is a new treatment under investigation for progressive multiple sclerosis (MS). It is taken as an intravenous infusion (drip) once a month. MS Trust · mstrust.org.uk About the postponement, from Yahoo Finance News (April 26, 2020):https://finance.yahoo.com/news/geneuro-financial-information-business-first-053000714.html Logged MS Speaks--online for 20 yearsSPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) 12/16/20 - 3/16/24.
